KORU Medical Systems Announces 510(k) Submission for Clearance of the FreedomEDGE® System with a Commercialized Oncology Biologic

Stock Information for KORU Medical Systems Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About KORU Medical Systems Inc.

KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System
KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
KORU Medical Systems, Inc. Appoints Eric Schiller as Chief Technology Officer
KORU Medical Systems to Present Promising Results on the Use of the FreedomEDGE® Syringe Infusion System in Infusion Centers at ESID/EHA/SIOPE Focused Symposium 2025
KORU Medical Systems to Participate in Upcoming Investor Conferences
KORU Medical Systems Announces 27% Q3 Revenue Growth and Raises 2025 Revenue Guidance
KORU Medical Systems Announces Development Agreement for Innovation in Subcutaneous Immunoglobulin Infusion Systems

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.